A Novel Targeted Microtubules Transformable Nanopeptide System Yields Strong Anti‐Prostate Cancer Effects by Suppressing Nuclear Translocation of Androgen …
L Wang, B Kong, J Wang, G Yang, X Wu… - Advanced …, 2024 - Wiley Online Library
The extended use of androgen deprivation therapy (ADT) may often lead to the progression
from castration‐sensitive prostate cancer (CSPC) to castration‐resistant prostate cancer …
from castration‐sensitive prostate cancer (CSPC) to castration‐resistant prostate cancer …
Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: a narrative review on behalf of the Meet-URO Group
The definition of" non-metastatic hormone-sensitive prostate cancer"(nmHSPC) can be
applied to patients with prostate cancer (PC) who are androgen-deprivation therapy-naïve …
applied to patients with prostate cancer (PC) who are androgen-deprivation therapy-naïve …
[HTML][HTML] Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?
MA Gómez-Aparicio, F López-Campos, D Buchser… - Cancers, 2024 - mdpi.com
Simple Summary First-line treatment options for patients with hormone-sensitive metastatic
prostate cancer (mHSPC) have evolved in recent years with treatment intensification …
prostate cancer (mHSPC) have evolved in recent years with treatment intensification …
Treatment intensification with novel hormonal therapy in castration-sensitive prostate cancer: Patient identification and clinical rationale
The clinical rationale for treatment of castration-sensitive prostate cancer (CSPC) with novel
hormonal therapy (NHT) or androgen receptor pathway inhibitor is reviewed. A PubMed …
hormonal therapy (NHT) or androgen receptor pathway inhibitor is reviewed. A PubMed …
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer
P Ravi, C Zhong, W Xie, E Kelly, B Whelpley… - European Urology …, 2024 - Elsevier
Background and objective It is unclear whether “total therapy”(androgen deprivation therapy
[ADT] with or without an androgen receptor pathway inhibitor [ARPI], metastasis-directed …
[ADT] with or without an androgen receptor pathway inhibitor [ARPI], metastasis-directed …
Falls and fractures in men with prostate cancer taking second-generation androgen receptor antagonists: A retrospective chart review
M Dennison, L Holle - Journal of Oncology Pharmacy …, 2024 - journals.sagepub.com
Introduction Second-generation androgen receptor antagonists, including enzalutamide,
apalutamide, and darolutamide, are commonly used to treat metastatic and non-metastatic …
apalutamide, and darolutamide, are commonly used to treat metastatic and non-metastatic …
[HTML][HTML] Network pharmacology combined with molecular docking revealed the potential targets of Coridius chinensis in prostate cancer treatment
M Zhang, J Ma, FY Zeng… - World Journal of Clinical …, 2024 - pmc.ncbi.nlm.nih.gov
BACKGROUND Prostate cancer (PCa) has high morbidity and mortality rates in elderly men.
With a history of thousands of years, traditional Chinese medicine derived from insects could …
With a history of thousands of years, traditional Chinese medicine derived from insects could …
ADT intensification to treat biochemically recurrent prostate cancer
MC Masone - Nature Reviews Urology, 2024 - nature.com
In the randomized phase III, open-label trial PRESTO, the effect of potentiating androgen
deprivation therapy (ADT) on improving oncological outcomes in patients with biochemically …
deprivation therapy (ADT) on improving oncological outcomes in patients with biochemically …
[HTML][HTML] Apalutamide/ADT does not appear to negatively impact QOL in recurrent prostate cancer
B Saylor - 2024 - urologytimes.com
In patients with prostate cancer with biochemical recurrence following primary therapy, an
intensified androgen blockade regimen consisting of apalutamide (Erleada) plus androgen …
intensified androgen blockade regimen consisting of apalutamide (Erleada) plus androgen …
Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review
Background and objective Biochemical recurrence (BCR) after primary definitive treatment
for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with …
for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with …